Table 4.
Long-term sequel according to diagnosis and treatment.
Diagnosis | Treatment | |||||
---|---|---|---|---|---|---|
SJS, N = 20 | Overlap-TEN, N = 16 | P value∗ | Supportive care, N = 8 | Systemic treatment, N = 28 | P value∗ | |
Long-term skin sequel, N (%) | ||||||
Dyspigmentation | 4 (20.0) | 14 (87.5) | <0.001 | 3 (37.5) | 15 (53.6) | 0.423 |
Xerosis | 1 (5.0) | 0 | 0.364 | 1 (12.5) | 0 | 0.058 |
Nail loss | 0 | 1 (6.2) | 0.257 | 0 | 1 (3.6) | 0.588 |
| ||||||
Long-term eye sequel, N (%) | ||||||
Dry eye | 4 (20.0) | 6 (37.5) | 0.244 | 4 (50.0) | 6 (21.6) | 0.112 |
Corneal scar | 0 | 4 (25.0) | 0.018 | 1 (12.5) | 3 (10.7) | 0.887 |
Keratopathy | 0 | 3 (18.8) | 0.043 | 2 (25.0) | 1 (3.6) | 0.053 |
Subconjunctival fibrosis | 0 | 1 (6.2) | 0.257 | 0 | 1 (3.6) | 0.588 |
| ||||||
Long-term GI sequel, N (%) | ||||||
Transaminitis | ||||||
Less than 3 m | 2 (10.0) | 5 (31.2) | 0.109 | 2 (25.0) | 5 (17.9) | 0.653 |
More than 3 m | 0 | 1 (6.2) | 0.257 | 0 | 1 (3.6) | 0.588 |
∗Significant values are shown in bold.